Hap Trading, LLC Atara Biotherapeutics, Inc. Call Options Transaction History

Hap Trading, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2020 Nov 13, 2020	SELL	$11.92 - $15.87 $120,392 - $160,287	-10,100 Closed	0 $0
Q2 2020 Aug 10, 2020	SELL	$7.53 - $14.93 $18,072 - $35,832	-2,400 Reduced 19.2%	10,100 $10,000
Q1 2020 May 08, 2020	BUY	$5.69 - $17.78 $71,125 - $222,250	12,500 New	12,500 $6,000
Q4 2019 Feb 11, 2020	SELL	$10.89 - $16.79 $1.93 Million - $2.98 Million	-177,600 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$12.03 - $19.94 $2.35 Million - $3.89 Million	-195,100 Reduced 52.35%	177,600 $62,000
Q2 2019 Aug 14, 2019	BUY	$19.05 - $41.04 $4.78 Million - $10.3 Million	251,100 Added 206.5%	372,700 $365,000
Q1 2019 May 10, 2019	BUY	$28.4 - $41.74 $3.45 Million - $5.08 Million	121,600 New	121,600 $357,000
Q3 2018 Nov 09, 2018	SELL	$35.05 - $43.5 $2.63 Million - $3.26 Million	-75,000 Closed	0 $0
Q2 2018 Aug 13, 2018	SELL	$35.15 - $51.45 $4.45 Million - $6.51 Million	-126,500 Reduced 62.78%	75,000 $122,000
Q1 2018 May 11, 2018	BUY	$18.0 - $48.35 $3.63 Million - $9.74 Million	201,500 New	201,500 $513,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $757M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.